Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMAVELOXOLONE Cause Product dose omission issue? 92 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 92 reports of Product dose omission issue have been filed in association with OMAVELOXOLONE (SKYCLARYS). This represents 7.4% of all adverse event reports for OMAVELOXOLONE.

92
Reports of Product dose omission issue with OMAVELOXOLONE
7.4%
of all OMAVELOXOLONE reports
1
Deaths
21
Hospitalizations

How Dangerous Is Product dose omission issue From OMAVELOXOLONE?

Of the 92 reports, 1 (1.1%) resulted in death, 21 (22.8%) required hospitalization.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMAVELOXOLONE. However, 92 reports have been filed with the FAERS database.

What Other Side Effects Does OMAVELOXOLONE Cause?

Fatigue (118) Nausea (101) Hepatic enzyme increased (100) Headache (83) Diarrhoea (77) Blood cholesterol increased (67) Muscle spasms (64) Abdominal pain upper (51) Atrial fibrillation (48) Urinary tract infection (47)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which OMAVELOXOLONE Alternatives Have Lower Product dose omission issue Risk?

OMAVELOXOLONE vs OMBITASVIR OMAVELOXOLONE vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMAVELOXOLONE vs OMEGA-3-ACID ETHYL ESTERS OMAVELOXOLONE vs OMEGA-3-CARBOXYLIC ACIDS OMAVELOXOLONE vs OMEGA-3 FATTY ACIDS

Related Pages

OMAVELOXOLONE Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue OMAVELOXOLONE Demographics